CN111407882A - 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 - Google Patents

神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 Download PDF

Info

Publication number
CN111407882A
CN111407882A CN202010283482.1A CN202010283482A CN111407882A CN 111407882 A CN111407882 A CN 111407882A CN 202010283482 A CN202010283482 A CN 202010283482A CN 111407882 A CN111407882 A CN 111407882A
Authority
CN
China
Prior art keywords
heart failure
ejection fraction
preserved ejection
nrg
neuregulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010283482.1A
Other languages
English (en)
Chinese (zh)
Inventor
周明东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Priority to CN202010283482.1A priority Critical patent/CN111407882A/zh
Publication of CN111407882A publication Critical patent/CN111407882A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202010283482.1A 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 Pending CN111407882A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010283482.1A CN111407882A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410550212.7A CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN202010283482.1A CN111407882A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201410550212.7A Division CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Publications (1)

Publication Number Publication Date
CN111407882A true CN111407882A (zh) 2020-07-14

Family

ID=55746124

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010283482.1A Pending CN111407882A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201410550212.7A Pending CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201580054201.2A Pending CN108064164A (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201410550212.7A Pending CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201580054201.2A Pending CN108064164A (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Country Status (10)

Country Link
US (3) US10561709B2 (cg-RX-API-DMAC10.html)
EP (2) EP3207940B1 (cg-RX-API-DMAC10.html)
JP (4) JP2017532343A (cg-RX-API-DMAC10.html)
KR (2) KR102603711B1 (cg-RX-API-DMAC10.html)
CN (3) CN111407882A (cg-RX-API-DMAC10.html)
AU (2) AU2015333335B2 (cg-RX-API-DMAC10.html)
CA (1) CA2963322A1 (cg-RX-API-DMAC10.html)
ES (1) ES2924395T3 (cg-RX-API-DMAC10.html)
RU (1) RU2017116973A (cg-RX-API-DMAC10.html)
WO (1) WO2016058493A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
DK3774859T3 (da) 2018-04-11 2024-05-27 Salubris Biotherapeutics Inc Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN113289002A (zh) * 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103857695A (zh) * 2011-10-10 2014-06-11 上海泽生科技开发有限公司 治疗心力衰竭的组份和方法
WO2014138502A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AU732027B2 (en) 1997-02-10 2001-04-12 Genentech Inc. Heregulin variants
EP1028735A4 (en) 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AU2001241839A1 (en) 2000-02-28 2001-09-12 Decode Genetics Ehf Human schizophrenia gene
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7375185B2 (en) 2000-09-12 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20060275770A1 (en) 2002-11-27 2006-12-07 Daniel Bednarik Heart failure gene determination and therapeutic screening
BRPI0410787A (pt) 2003-05-21 2006-06-20 Univ Texas inibição da proteìna cinase c-mu (pkd) como um tratamento para hipertrofia cardìaca e insuficiência cardìaca
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
US20080213395A1 (en) 2004-10-14 2008-09-04 Adventures Plus Pty Ltd Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
DK2115477T3 (en) 2007-01-25 2015-08-10 Hoffmann La Roche USE OF IGFBP-7 IN THE EVIDENCE OF HEART FAILURE
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
CN101310766B (zh) * 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP3338791B1 (en) * 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
CN102470161A (zh) * 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
WO2010142141A1 (en) * 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2011112864A1 (en) 2010-03-10 2011-09-15 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
CN108420827A (zh) 2010-07-22 2018-08-21 雷文制药有限公司 包含磁偶极子稳定化溶液的组合物及其用途
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
RU2650635C2 (ru) 2012-10-08 2018-04-16 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
JP2024094951A (ja) 2022-12-28 2024-07-10 セイコーエプソン株式会社 チクソ成形体およびチクソ成形用材料

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103857695A (zh) * 2011-10-10 2014-06-11 上海泽生科技开发有限公司 治疗心力衰竭的组份和方法
WO2014138502A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KATRIEN LEMMENS ET AL.: "Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease Implications for Therapy of Heart Failure", vol. 116, pages 954 - 960, XP093053923, DOI: 10.1161/CIRCULATIONAHA.107.690487 *
中国生物技术发展中心组织: "《中国现代医学科技创新能力国际比较》", vol. 1, 31 October 2009, 中国医药科技出版社, pages: 920 *
欧柏青等: "《心力衰竭诊治精要》", vol. 1, 31 January 2013, 湖南师范大学出版社, pages: 80 - 81 *
肖坚等: "Neuregulin-1 在心血管系统的研究进展", vol. 28, no. 3, pages 303 - 306 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法

Also Published As

Publication number Publication date
KR20170066440A (ko) 2017-06-14
JP7876185B2 (ja) 2026-06-19
KR102603711B1 (ko) 2023-11-20
US20170232068A1 (en) 2017-08-17
AU2021258063B2 (en) 2025-02-27
CA2963322A1 (en) 2016-04-21
KR20230159650A (ko) 2023-11-21
AU2015333335B2 (en) 2021-08-05
CN105561298A (zh) 2016-05-11
RU2017116973A3 (cg-RX-API-DMAC10.html) 2019-05-06
AU2015333335A1 (en) 2017-04-20
EP3207940A4 (en) 2018-06-06
EP3207940B1 (en) 2022-06-01
JP2024164068A (ja) 2024-11-26
WO2016058493A1 (zh) 2016-04-21
JP2017532343A (ja) 2017-11-02
JP2022153417A (ja) 2022-10-12
US20220354928A1 (en) 2022-11-10
EP4112068A1 (en) 2023-01-04
AU2021258063A1 (en) 2021-11-25
US20200368317A1 (en) 2020-11-26
US10561709B2 (en) 2020-02-18
JP2020193217A (ja) 2020-12-03
CN108064164A (zh) 2018-05-22
ES2924395T3 (es) 2022-10-06
EP3207940A1 (en) 2017-08-23
RU2017116973A (ru) 2018-11-19

Similar Documents

Publication Publication Date Title
AU2021258063B2 (en) Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
JP7761964B2 (ja) 心不全の治療用組成物
EP3199174B1 (en) Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia
EP2440236B1 (en) Neuregulin based methods for treating heart failure
KR20160009575A (ko) 심부전을 치료하기 위한 뉴레귤린의 연장 방출
US20180104311A1 (en) Neuregulin based methods for treating heart failure
CN112585159A (zh) 神经调节蛋白多肽片段及其用途
KR20220145870A (ko) 뉴레귤린, 및 조성물을 사용함으로써 심부전을 예방, 치료 또는 지연시키기 위한 방법
HK1241737B (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
HK1241737A1 (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
JP2022516199A (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
WO2024067817A1 (zh) 神经调节蛋白及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200714